Advertisement
UK markets close in 7 hours 31 minutes
  • FTSE 100

    7,955.73
    +23.75 (+0.30%)
     
  • FTSE 250

    19,784.76
    -25.90 (-0.13%)
     
  • AIM

    741.84
    -0.27 (-0.04%)
     
  • GBP/EUR

    1.1681
    +0.0012 (+0.10%)
     
  • GBP/USD

    1.2608
    -0.0030 (-0.24%)
     
  • Bitcoin GBP

    56,013.23
    +829.95 (+1.50%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • S&P 500

    5,248.49
    +44.91 (+0.86%)
     
  • DOW

    39,760.08
    +477.75 (+1.22%)
     
  • CRUDE OIL

    81.71
    +0.36 (+0.44%)
     
  • GOLD FUTURES

    2,216.20
    +3.50 (+0.16%)
     
  • NIKKEI 225

    40,168.07
    -594.66 (-1.46%)
     
  • HANG SENG

    16,541.42
    +148.58 (+0.91%)
     
  • DAX

    18,497.70
    +20.61 (+0.11%)
     
  • CAC 40

    8,230.45
    +25.64 (+0.31%)
     

Is This Unknown Growth Stock a Buy After Its Blast Off?

Alnylam Pharmaceuticals' (NASDAQ: ALNY) stock went vertical in the past month -- up over 50% -- and there might be even more growth on the way. Sales of its top-earning medicines are booming, and breakthroughs in clinical trials have added to the enthusiasm. Alnylam has a small handful of medicines on the market, led by its drugs Onpattro and Amvuttra, which are intended to treat peripheral neuropathy caused by hereditary transthyretin amyloidosis (ATTR), which is a rare but deadly and progressively worsening heart disease.